This study is being done to investigate the effects (good and bad) of Rituximab for the
treatment of an autoimmune eye disease called Graves' ophthalmopathy. This disease has proven
to be difficult to treat. Rituximab is a monoclonal antibody that depletes a line of cells
involved in the autoimmune response. The study hypotheses is that rituximab is effective in
the treatment of patients with moderate to severe active Graves' ophthalmopathy.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Rebecca Bahn
Collaborators:
National Center for Research Resources (NCRR) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)